NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

IDEAYA Biosciences logo
$26.30 -1.10 (-4.01%)
As of 11:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

Advanced

Key Stats

Today's Range
$26.32
▼
$27.53
50-Day Range
$27.40
▼
$39.71
52-Week Range
$26.32
▼
$42.68
Volume
323,998 shs
Average Volume
1.03 million shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.55
Consensus Rating
Moderate Buy

Company Overview

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets.

The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations. These candidates remain under clinical investigation; IDEAYA does not sell approved medicines.

Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and advances clinical development programs, including through collaborations with other biotechnology and pharmaceutical companies. Yujiro S. Hata is the company’s chief executive officer.

AI Generated. May Contain Errors.

IDEAYA Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

IDYA MarketRank™: 
3.065182617965 of 5 stars

IDEAYA Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 326th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    IDEAYA Biosciences has a consensus price target of $49.55, representing about 80.8% upside from its current price of $27.40.

  • Amount of Analyst Coverage

    IDEAYA Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IDEAYA Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($4.63) to ($4.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEAYA Biosciences is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEAYA Biosciences is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IDEAYA Biosciences has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.94% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.87.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently decreased by 9.28%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    IDEAYA Biosciences does not currently pay a dividend.

  • Dividend Growth

    IDEAYA Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    IDEAYA Biosciences has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $985,305.00 in company stock.

  • Percentage Held by Insiders

    4.70% of the stock of IDEAYA Biosciences is held by insiders.

  • Percentage Held by Institutions

    98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEAYA Biosciences' insider trading history.
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDYA Stock News Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
IDEAYA Biosciences (IDYA) vs. The Competition Financial Survey
Transcript : IDEAYA Biosciences, Inc. - Special Call
See More Headlines

IDYA Stock Analysis - Frequently Asked Questions

IDEAYA Biosciences' stock was trading at $34.57 at the beginning of 2026. Since then, IDYA stock has decreased by 20.7% and is now trading at $27.40.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its earnings results on Tuesday, November, 3rd. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.18) by $0.04. The firm's quarterly revenue was up 14.6% on a year-over-year basis.

IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

IDEAYA Biosciences' top institutional shareholders include State Street Corp (4.06%), Goldman Sachs Group Inc. (1.50%), Candriam S.C.A. (1.26%) and Fisher Asset Management LLC (0.84%). Insiders that own company stock include Yujiro S Hata, Jeffrey Stein, Briseno Andres Ruiz and Michael Anthony White.
View institutional ownership trends
.

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Micron Technology (MU), Iovance Biotherapeutics (IOVA), Advanced Micro Devices (AMD), Tesla (TSLA) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/03/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IDYA
CIK
1676725
Fax
N/A
Employees
145
Year Founded
2015

Price Target and Rating

High Price Target
$66.00
Low Price Target
$35.00
Potential Upside/Downside
+88.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.70 million
Net Margins
-1,157.18%
Pretax Margin
-1,149.62%
Return on Equity
-39.78%
Return on Assets
-36.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.04
Quick Ratio
9.04

Sales & Book Value

Annual Sales
$218.71 million
Price / Sales
11.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.29 per share
Price / Book
2.33

Miscellaneous

Outstanding Shares
96,690,000
Free Float
92,150,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
0.08

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:IDYA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners